FDA Warns of Liver Damage Risk Possibly Posed By Samsca
The Food and Drug Administration is warning doctors and consumers alike of the potential liver damage that could result due to the consumption of the drug known as Samsca, or tolvaptan. During a three year clinical trial partially involving the use of placebos, three patients experienced liver enzyme abnormalities. Doctors stopped providing the persons with treatment and their condition improved. Various experts were asked to weigh in on the findings and came to the conclusion that patients taking Samsca could potentially face long-lasting or even fatal damage to their livers. Doctors are being asked to be attuned to patients who complain of jaundice, dark urine, anorexia, exhaustion, or more. Liver tests should then be conducted and discontinuation should occur if a serious injury is suspected.
Click here to learn more about the findings.